Form 4: Quest Diagnostics SVP Sells Shares After Award

Quest Diagnostics' SVP & General Counsel, Michael E. Prevoznik, reported the acquisition of shares from a performance award and subsequent sales for tax obligations and a pre-planned 10b5-1 plan.

Summary

• Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics Inc. (DGX), reported transactions involving common stock.
• On March 4, 2026, Prevoznik acquired 7,232 shares of common stock at $204.86 per share, stemming from the settlement of a performance stock award.
• Concurrently, on March 4, 2026, 3,354 shares were disposed of at $204.86 per share to cover tax withholding obligations related to the performance stock award.
• On March 5, 2026, an additional 3,878 shares were sold at $206.21 per share, executed under a pre-arranged Rule 10b5-1 sales plan.
• Following these transactions, Prevoznik directly holds 37,557 shares and indirectly holds 5,737 shares through company 401(k)/SDCP plans, totaling 43,294 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The acquisition of shares via a performance award is positive, indicating executive performance, while the sales are routine for tax purposes and a pre-planned strategy, not necessarily signaling a lack of confidence.

Positives

• Acquisition of 7,232 shares of common stock at $204.86 as settlement of a performance stock award indicates successful achievement of performance metrics.

Negatives

• Disposition of 3,878 shares at $206.21 under a Rule 10b5-1 plan represents an insider sale, which can sometimes be viewed negatively by the market, though it was pre-planned.
• Disposition of 3,354 shares at $204.86 to cover tax withholding reduces direct ownership.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that routine insider transactions, especially those related to performance awards and pre-planned sales (10b5-1 plans), are common across industries and generally do not signal significant shifts in company fundamentals or broader industry trends unless they are unusually large or frequent.

Related Party Transactions

• The acquisition of 7,232 shares was a settlement of a performance stock award from Quest Diagnostics Incorporated, the issuer.

Stakeholder Impact

• Shareholders: The transactions represent routine insider activity, with a net reduction in direct ownership due to tax-related sales and a 10b5-1 plan sale, which is generally not a significant concern unless the sales are substantial or unplanned.
• Employees: The performance stock award indicates the company's compensation structure for executives, potentially motivating performance.

Key Dates

Recommendation

The filing details routine insider transactions, including the vesting of a performance award and subsequent sales for tax purposes and a pre-arranged 10b5-1 plan. These actions do not provide new fundamental information about Quest Diagnostics' operational performance or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

Quest Diagnostics, DGX, Michael E. Prevoznik, Insider Trading, Form 4, Stock Award, 10b5-1 Plan, Share Sale, Corporate Officer